Around the Practice: ctDNA in Treatment Decisions and Monitoring - Episode 1

Scenario 1: ctDNA to Determine Use of Adjuvant Chemotherapy in Stage II CRC

July 28, 2022

John Strickler, MD, Aditya Bardia, MD, MPH, Martin Dietrich, MD, PhD

Centering discussion on a patient scenario of stage II colorectal cancer, expert oncologists consider how ctDNA may inform use of adjuvant chemotherapy in this setting.

Now Viewing

EP. 1: Scenario 1: ctDNA to Determine Use of Adjuvant Chemotherapy in Stage II CRC

EP. 2: Future Role of ctDNA in CRC: Surveillance and Treatment Selection

EP. 3: Understanding the Mechanisms and Use of ctDNA and MRD Testing

EP. 4: Identifying Use of ctDNA Across Tumor Types